DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Companies / Altesa BioSciences, Inc.
Altesa BioSciences, Inc.
Series BCollege Park, GAPharmaceuticals
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- Decline to Disclosesec.gov
- Rounds on record
- 2
- Disclosed raised
- $75.0Msum of rounds with a disclosed amount only
- Named investors
- 5
Financing history
2 rounds
- Feb 19, 2026Series B · $75.0M (disclosed)Forbion (lead)Sanofi (participant)Pitango International Mc 2019 Ltd. (participant)Medicxi (participant)Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases”
- Feb 13, 2026Form D equity offering · $75.0M (form d sold) · 17 investorsFact SEC EDGAR Form D data sets (quarterly) · “Altesa BioSciences, Inc. filed Form D: $74,999,986 sold of $74,999,986, Pharmaceuticals”
Investors on record
5 edges
- Pitango Healthtech Mc 2022 Ltd board only, Ittai Harel (strongly supported) Inference sec.gov
- Forbion round, lead Fact prnewswire.com
- Medicxi round, participant Fact prnewswire.com
- Pitango International Mc 2019 Ltd. round, participant Fact prnewswire.com
- Sanofi round, participant Fact prnewswire.com
People
3 officers, 5 directors
- Andrew Drechsler Executive Officer sec.gov
- Brett Giroir Executive Officer/Director sec.gov
- John Clerici Executive Officer sec.gov
- Moncef Slaoui Director Fact
- Seth Rudnick Director Fact
- JON Edwards Director Fact
- Ittai Harel Director Inference
- Nicholas Williams Director Fact
Timeline
2
- Feb 23, 2026Altesa BioSciences, Inc. filed Form D: $74,999,986 sold of $74,999,986, PharmaceuticalsForm D filed Fact SEC EDGAR Form D data sets (quarterly)
- Feb 19, 2026Altesa BioSciences announced Series B of $75,000,000, led by ForbionRound announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
15 observations
Every observation on this company
- Entity type: Corporation Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Form D industry group: Pharmaceuticals Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amendment: false Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Revenue range (Form D): Decline to Disclose Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Incorporated: overFiveYears Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Jurisdiction: DELAWARE Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amount sold (Form D): $75.0M Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Offering amount (Form D): $75.0M Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Exemptions: 06b Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- First sale: 2026-02-13 Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Investors (Form D): 17 Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Minimum investment (Form D): 0 Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Securities offered: equity Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Office address: 1930 HARVARD AVENUE, COLLEGE PARK, GA, 30337 Feb 23, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Round announced: Series B $75,000,000 Feb 19, 2026 Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)